Loxonin (Loxoprofen Sodium)


Indications and Reactions:

Role Indications Reactions
Secondary
Drug Use For Unknown Indication 23.6%
Hypertension 10.9%
Pyrexia 8.2%
Lung Adenocarcinoma 7.3%
Rheumatoid Arthritis 6.4%
Nasopharyngitis 5.5%
Pain 5.5%
Back Pain 4.5%
Influenza 3.6%
Non-small Cell Lung Cancer 3.6%
Osteitis Deformans 2.7%
Osteoporosis 2.7%
Prophylaxis 2.7%
Biliary Tract Infection 1.8%
Epilepsy 1.8%
Hypercholesterolaemia 1.8%
Hyperlipidaemia 1.8%
Ill-defined Disorder 1.8%
Insomnia 1.8%
Insulin-requiring Type Ii Diabetes Mellitus 1.8%
Pruritus Generalised 11.5%
Flushing 7.7%
Pneumonia Aspiration 7.7%
Urine Output Decreased 7.7%
Vomiting 7.7%
Blood Alkaline Phosphatase Increased 3.8%
Blood Creatine Phosphokinase Increased 3.8%
Dyspnoea 3.8%
Fall 3.8%
Glomerulonephritis Membranous 3.8%
Haemorrhage 3.8%
Hepatic Function Abnormal 3.8%
Intra-abdominal Haemorrhage 3.8%
Leukoencephalopathy 3.8%
Loss Of Consciousness 3.8%
Lung Infiltration 3.8%
Melaena 3.8%
Meniere's Disease 3.8%
Metastatic Pain 3.8%
Multiple Drug Overdose Intentional 3.8%
Concomitant
Multiple Myeloma 16.5%
Lung Adenocarcinoma 15.4%
Non-hodgkin's Lymphoma 9.3%
Rheumatoid Arthritis 8.8%
Lupus Nephritis 5.6%
Lung Squamous Cell Carcinoma Stage Unspecified 4.9%
Colorectal Cancer 4.3%
Cerebral Infarction 4.1%
Drug Use For Unknown Indication 3.5%
Non-small Cell Lung Cancer 3.5%
Insomnia 3.3%
Diabetes Mellitus 3.1%
Lymphoma 3.1%
Parkinson's Disease 2.5%
Prophylaxis 2.5%
Staphylococcal Infection 2.5%
Hypertension 2.1%
Colorectal Cancer Metastatic 1.9%
Back Pain 1.6%
Type 2 Diabetes Mellitus 1.6%
White Blood Cell Count Decreased 22.8%
Rash 10.7%
Vomiting 8.6%
Pyrexia 7.6%
Respiratory Failure 7.6%
Platelet Count Decreased 6.6%
White Blood Cell Count Increased 5.1%
Malignant Neoplasm Progression 3.6%
Stomatitis 3.6%
Pneumonia 2.5%
Rhabdomyolysis 2.5%
Thrombocytopenia 2.5%
Hepatic Function Abnormal 2.0%
Interstitial Lung Disease 2.0%
Liver Disorder 2.0%
Pneumocystis Jiroveci Pneumonia 2.0%
Renal Impairment 2.0%
Staphylococcal Infection 2.0%
Stevens-johnson Syndrome 2.0%
Ventricular Extrasystoles 2.0%

Drug Data